{
    "info": {
        "nct_id": "NCT03942224",
        "official_title": "A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study)",
        "inclusion_criteria": "* Patients must meet the following criteria on screening examination to be eligible to participate in the study. All laboratory assessments should be performed within 21 days of initiation of protocol therapy unless otherwise specified. Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements\n* Subject has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Have documented multiple myeloma as defined by the International Myeloma Working Group (IMWG) 2014 criteria including: Clonal bone marrow plasma cells ≥ 10% (If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement). In addition, the patient must meet one of the criteria in d1 or d2:\n\n  * Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically (one or more of the following):\n\n    * Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)\n    * Renal insufficiency: Creatinine clearance (CrCl) < 40 mL/min (measured or estimated by validated equations) or serum creatinine > 177 umol/L (> 2 mg/dL)\n    * Anemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value < 100 g/L\n    * Bone lesions: 1 or more osteolytic lesions on skeletal radiography, computed tomography (CT), or magnetic resonance imaging (MRI)\n\n      * Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used\n  * Any one or more of the following:\n\n    * Clonal bone marrow plasma cell percentage ≥ 60%\n\n      * Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used\n    * Involved:uninvolved serum free light chain (FLC) ratio > 100\n\n      * These values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The involved FLC must be ≥ 100 mg/L\n    * > 1 focal lesions on MRI studies; Each focal lesion must be 5 mm or more in size\n* Measurable disease as defined by any of the following:\n\n  * Serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours. Note: All attempts should be made to determine eligibility of the subject based on the central laboratory results of screening blood and urine M-protein measurements. In exceptional circumstances, the local laboratory results for blood and urine M-protein measurements may be used to determine eligibility, but only if the results are clearly (eg, 25% or more) above the thresholds for measurability; or\n  * Immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), or immunoglobulin M (IgM) multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or\n  * Light chain multiple myeloma without measurable disease in the urine: serum Ig FLC ≥ 10 mg/dL and abnormal serum Ig kappa/lambda FLC ratio\n* Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed\n* Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed\n* Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed\n* Female patients who:\n\n  * Are postmenopausal for at least 1 year before the screening visit, OR\n  * Are surgically sterile, OR\n  * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR\n  * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)\n  * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International Unit (mIU)/mL within 10-14 days prior to and again within 24 hours of starting study drugs\n* Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:\n\n  * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR\n  * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Diagnosed with smoldering multiple myeloma (MM), monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis or primary or secondary plasma cell leukemia\n* Participant has ≥ grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy\n* Renal insufficiency, defined as creatinine clearance ≤ 30 mL/min (either actual or calculated value), within 21 days of initiation of protocol therapy. The Cockcroft-Gault formula should be used for calculating creatinine clearance values\n* Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment\n* Participants with an absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation. Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation\n* Participants with hemoglobin level < 7.0 g/dL, at time of screening. Transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation\n* Participants with hepatic impairment, defined as bilirubin ≥ 1.5 x institutional upper limit of normal (ULN) or aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN, within 21 days of initiation of protocol therapy\n* Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent) for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to study treatment.)\n* Steroids more than 160 mg IV equivalents of dexamethasone or bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents\n* Known significant cardiac abnormalities including:\n\n  * Congestive heart failure, New York Heart Association (NYHA) class III or IV\n  * Uncontrolled angina, arrhythmia or hypertension\n  * Myocardial infarction within the past six months\n  * Any other uncontrolled or severe cardiovascular condition\n  * Prior cerebrovascular event with residual neurologic deficit\n* Known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal\n* Has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification\n* Serious, intercurrent illness including, but not limited to, clinically relevant active infection, uncontrolled diabetes mellitus, or serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis\n* Seropositive for human immunodeficiency virus (HIV)\n* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n* Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)\n* Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study\n* Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection\n* Known hypersensitivity to acyclovir or similar anti-viral drug\n* Known intolerance to steroid therapy\n* Participants with known central nervous system (CNS) involvement\n* Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol\n* Female participants pregnant or breast-feeding\n* Participants who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery\n* Participants with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff\n* Prior exposure to anti-CD38 therapy\n* Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib\n* Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol\n* Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial\n* Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* > 1 focal lesions on MRI studies; Each focal lesion must be 5 mm or more in size",
                "criterions": [
                    {
                        "exact_snippets": "> 1 focal lesions on MRI studies",
                        "criterion": "number of focal lesions on MRI",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lesions"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Each focal lesion must be 5 mm or more in size",
                        "criterion": "focal lesion size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "mm"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "> 1 focal lesions on MRI studies",
                        "criterion": "number of focal lesions on MRI",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lesions"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Each focal lesion must be 5 mm or more in size",
                        "criterion": "focal lesion size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "mm"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed",
                "criterions": [
                    {
                        "exact_snippets": "Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed",
                        "criterion": "blood donation",
                        "requirement": {
                            "requirement_type": "abstinence period",
                            "expected_value": "during therapy on study and for 8 weeks after therapy is completed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed",
                        "criterion": "blood donation",
                        "requirement": {
                            "requirement_type": "abstinence period",
                            "expected_value": "during therapy on study and for 8 weeks after therapy is completed"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)",
                "criterions": [
                    {
                        "exact_snippets": "Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 0.25,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 2.75,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 11,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 0.25,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal (ULN) or > 2.75 mmol/L (> 11 mg/dL)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 2.75,
                                        "unit": "mmol/L"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 11,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Are surgically sterile, OR",
                "criterions": [
                    {
                        "exact_snippets": "Are surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Are surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female patients who:",
                "criterions": [
                    {
                        "exact_snippets": "Female patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Female patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed",
                        "criterion": "prior bortezomib treatment",
                        "requirement": {
                            "requirement_type": "maximum number of doses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed",
                        "criterion": "prior bortezomib treatment",
                        "requirement": {
                            "requirement_type": "dose per administration",
                            "expected_value": {
                                "operator": "=",
                                "value": 1.3,
                                "unit": "mg/m²"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed",
                        "criterion": "prior bortezomib treatment",
                        "requirement": {
                            "requirement_type": "maximum number of doses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with bortezomib up to 2 doses of 1.3 mg/m² each dosing equivalent is allowed",
                        "criterion": "prior bortezomib treatment",
                        "requirement": {
                            "requirement_type": "dose per administration",
                            "expected_value": {
                                "operator": "=",
                                "value": 1.3,
                                "unit": "mg/m²"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subject has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care",
                "criterions": [
                    {
                        "exact_snippets": "Subject has given voluntary signed written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subject has given voluntary signed written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "before performance of any study-related procedure that is not part of normal medical care",
                        "criterion": "timing of informed consent",
                        "requirement": {
                            "requirement_type": "before non-standard procedures",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subject has given voluntary signed written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subject has given voluntary signed written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "before performance of any study-related procedure that is not part of normal medical care",
                        "criterion": "timing of informed consent",
                        "requirement": {
                            "requirement_type": "before non-standard procedures",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Measurable disease as defined by any of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Involved:uninvolved serum free light chain (FLC) ratio > 100",
                "criterions": [
                    {
                        "exact_snippets": "Involved:uninvolved serum free light chain (FLC) ratio > 100",
                        "criterion": "serum free light chain (FLC) ratio",
                        "requirement": {
                            "requirement_type": "ratio",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Involved:uninvolved serum free light chain (FLC) ratio > 100",
                        "criterion": "serum free light chain (FLC) ratio",
                        "requirement": {
                            "requirement_type": "ratio",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any one or more of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Any one or more of the following:",
                        "criterion": "at least one of the following criteria (not specified in this line)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any one or more of the following:",
                        "criterion": "at least one of the following criteria (not specified in this line)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must meet the following criteria on screening examination to be eligible to participate in the study. All laboratory assessments should be performed within 21 days of initiation of protocol therapy unless otherwise specified. Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements",
                "criterions": [
                    {
                        "exact_snippets": "Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements",
                        "criterion": "willingness and ability to comply with protocol requirements",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements",
                        "criterion": "willingness and ability to comply with protocol requirements",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR",
                "criterions": [
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "effective barrier contraception"
                        }
                    },
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "entire study treatment period and through 90 days after the last dose of study drug"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "effective barrier contraception"
                        }
                    },
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "entire study treatment period and through 90 days after the last dose of study drug"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "steroids"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": "to stabilize the patient"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 160,
                                "unit": "mg IV equivalents of dexamethasone"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "steroids"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": "to stabilize the patient"
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment to stabilize the patient with steroids up to 160 mg IV equivalents of dexamethasone is allowed",
                        "criterion": "prior steroid treatment",
                        "requirement": {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 160,
                                "unit": "mg IV equivalents of dexamethasone"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR",
                "criterions": [
                    {
                        "exact_snippets": "of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        }
                    },
                    {
                        "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "simultaneous use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "from the time of signing the informed consent form through 90 days after the last dose of study drug"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirement": {
                        "requirement_type": "status",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "number of methods",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "methods"
                                }
                            }
                        },
                        {
                            "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "simultaneous use",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "duration",
                                "expected_value": "from the time of signing the informed consent form through 90 days after the last dose of study drug"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Renal insufficiency: Creatinine clearance (CrCl) < 40 mL/min (measured or estimated by validated equations) or serum creatinine > 177 umol/L (> 2 mg/dL)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance (CrCl) < 40 mL/min (measured or estimated by validated equations)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine > 177 umol/L (> 2 mg/dL)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 177,
                                "unit": "umol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine > 177 umol/L (> 2 mg/dL)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Creatinine clearance (CrCl) < 40 mL/min (measured or estimated by validated equations)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine > 177 umol/L (> 2 mg/dL)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 177,
                                "unit": "umol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum creatinine > 177 umol/L (> 2 mg/dL)",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Male patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "even if surgically sterilized (ie, status post-vasectomy)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "status post-vasectomy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to one of the following",
                        "criterion": "agreement to contraception or related protocol",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Male patients",
                                "criterion": "sex",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": "male"
                                }
                            },
                            {
                                "exact_snippets": "even if surgically sterilized (ie, status post-vasectomy)",
                                "criterion": "surgical sterilization status",
                                "requirement": {
                                    "requirement_type": "status post-vasectomy",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "must agree to one of the following",
                        "criterion": "agreement to contraception or related protocol",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically (one or more of the following):",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder",
                        "criterion": "end organ damage attributable to plasma cell proliferative disorder",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder",
                        "criterion": "end organ damage attributable to plasma cell proliferative disorder",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Anemia: hemoglobin value of > 20 g/L below the lower limit of normal, or a hemoglobin value < 100 g/L",
                "criterions": [
                    {
                        "exact_snippets": "Anemia: hemoglobin value of > 20 g/L below the lower limit of normal",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": -20,
                                "unit": "g/L below lower limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "hemoglobin value < 100 g/L",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "g/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Anemia: hemoglobin value of > 20 g/L below the lower limit of normal",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": -20,
                                "unit": "g/L below lower limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "hemoglobin value < 100 g/L",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "g/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Are postmenopausal for at least 1 year before the screening visit, OR",
                "criterions": [
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Seropositive for human immunodeficiency virus (HIV)",
                "criterions": [
                    {
                        "exact_snippets": "Seropositive for human immunodeficiency virus (HIV)",
                        "criterion": "human immunodeficiency virus (HIV) serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Seropositive for human immunodeficiency virus (HIV)",
                        "criterion": "human immunodeficiency virus (HIV) serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Myocardial infarction within the past six months",
                "criterions": [
                    {
                        "exact_snippets": "Myocardial infarction within the past six months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "occurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Myocardial infarction within the past six months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "occurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                "criterions": [
                    {
                        "exact_snippets": "Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg])",
                        "criterion": "hepatitis B serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg])",
                        "criterion": "hepatitis B serostatus",
                        "requirement": {
                            "requirement_type": "HBsAg test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                        "criterion": "resolved hepatitis B infection",
                        "requirement": {
                            "requirement_type": "HBsAg test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                        "criterion": "resolved hepatitis B infection",
                        "requirement": {
                            "requirement_type": "anti-HBc and/or anti-HBs test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                        "criterion": "resolved hepatitis B infection",
                        "requirement": {
                            "requirement_type": "HBV DNA PCR screening",
                            "expected_value": "required"
                        }
                    },
                    {
                        "exact_snippets": "Those who are PCR positive will be excluded.",
                        "criterion": "HBV DNA PCR result",
                        "requirement": {
                            "requirement_type": "PCR result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                        "criterion": "HBV vaccination status and serology",
                        "requirement": {
                            "requirement_type": "anti-HBs test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                        "criterion": "HBV vaccination status and serology",
                        "requirement": {
                            "requirement_type": "other HBV serologic markers",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                        "criterion": "HBV vaccination status and serology",
                        "requirement": {
                            "requirement_type": "history of HBV vaccination",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                        "criterion": "HBV vaccination status and serology",
                        "requirement": {
                            "requirement_type": "need for HBV DNA PCR testing",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg])",
                                "criterion": "hepatitis B serostatus",
                                "requirement": {
                                    "requirement_type": "seropositivity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg])",
                                "criterion": "hepatitis B serostatus",
                                "requirement": {
                                    "requirement_type": "HBsAg test result",
                                    "expected_value": "positive"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                                        "criterion": "resolved hepatitis B infection",
                                        "requirement": {
                                            "requirement_type": "HBsAg test result",
                                            "expected_value": "negative"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                                        "criterion": "resolved hepatitis B infection",
                                        "requirement": {
                                            "requirement_type": "anti-HBc and/or anti-HBs test result",
                                            "expected_value": "positive"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.",
                                        "criterion": "resolved hepatitis B infection",
                                        "requirement": {
                                            "requirement_type": "HBV DNA PCR screening",
                                            "expected_value": "required"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Those who are PCR positive will be excluded.",
                                        "criterion": "HBV DNA PCR result",
                                        "requirement": {
                                            "requirement_type": "PCR result",
                                            "expected_value": "negative"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                                            "criterion": "HBV vaccination status and serology",
                                            "requirement": {
                                                "requirement_type": "anti-HBs test result",
                                                "expected_value": "positive"
                                            }
                                        },
                                        {
                                            "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                                            "criterion": "HBV vaccination status and serology",
                                            "requirement": {
                                                "requirement_type": "other HBV serologic markers",
                                                "expected_value": "negative"
                                            }
                                        },
                                        {
                                            "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                                            "criterion": "HBV vaccination status and serology",
                                            "requirement": {
                                                "requirement_type": "history of HBV vaccination",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                                            "criterion": "HBV vaccination status and serology",
                                            "requirement": {
                                                "requirement_type": "need for HBV DNA PCR testing",
                                                "expected_value": false
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not",
                "criterions": [
                    {
                        "exact_snippets": "Patients that have previously been treated with ixazomib",
                        "criterion": "prior treatment with ixazomib",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "participated in a study with ixazomib whether treated with ixazomib or not",
                        "criterion": "prior participation in ixazomib study",
                        "requirement": {
                            "requirement_type": "history of study participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients that have previously been treated with ixazomib",
                        "criterion": "prior treatment with ixazomib",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "participated in a study with ixazomib whether treated with ixazomib or not",
                        "criterion": "prior participation in ixazomib study",
                        "requirement": {
                            "requirement_type": "history of study participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with hemoglobin level < 7.0 g/dL, at time of screening. Transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation",
                "criterions": [
                    {
                        "exact_snippets": "hemoglobin level < 7.0 g/dL, at time of screening",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation",
                        "criterion": "blood transfusion within 7 days prior to screening evaluation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "hemoglobin level < 7.0 g/dL, at time of screening",
                                "criterion": "hemoglobin level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 7.0,
                                        "unit": "g/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Transfusion may not be used to meet eligibility criteria within 7 days of obtaining screening evaluation",
                                "criterion": "blood transfusion within 7 days prior to screening evaluation",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort",
                "criterions": [
                    {
                        "exact_snippets": "Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)",
                        "criterion": "systemic treatment with strong CYP3A inducers",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)",
                        "criterion": "systemic treatment with strong CYP3A inducers",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "use of St. John's wort",
                        "criterion": "use of St. John's wort",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)",
                                "criterion": "systemic treatment with strong CYP3A inducers",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital)",
                                "criterion": "systemic treatment with strong CYP3A inducers",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "use of St. John's wort",
                        "criterion": "use of St. John's wort",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior exposure to anti-CD38 therapy",
                "criterions": [
                    {
                        "exact_snippets": "Prior exposure to anti-CD38 therapy",
                        "criterion": "anti-CD38 therapy",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior exposure to anti-CD38 therapy",
                    "criterion": "anti-CD38 therapy",
                    "requirement": {
                        "requirement_type": "prior exposure",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal",
                "criterions": [
                    {
                        "exact_snippets": "Known chronic obstructive pulmonary disease",
                        "criterion": "chronic obstructive pulmonary disease (COPD)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "forced expiratory volume in 1 second (FEV1) < 50% of predicted normal",
                        "criterion": "forced expiratory volume in 1 second (FEV1)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "% of predicted normal"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Known chronic obstructive pulmonary disease",
                    "criterion": "chronic obstructive pulmonary disease (COPD)",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "forced expiratory volume in 1 second (FEV1) < 50% of predicted normal",
                    "criterion": "forced expiratory volume in 1 second (FEV1)",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<",
                            "value": 50,
                            "unit": "% of predicted normal"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib",
                "criterions": [
                    {
                        "exact_snippets": "Radiotherapy within 14 days before enrollment",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib",
                        "criterion": "radiotherapy (small involved field)",
                        "requirement": {
                            "requirement_type": "time since last radiotherapy (small field)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Radiotherapy within 14 days before enrollment",
                            "criterion": "radiotherapy",
                            "requirement": {
                                "requirement_type": "time since last radiotherapy",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 14,
                                    "unit": "days"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib",
                            "criterion": "radiotherapy (small involved field)",
                            "requirement": {
                                "requirement_type": "time since last radiotherapy (small field)",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 7,
                                    "unit": "days"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known intolerance to steroid therapy",
                "criterions": [
                    {
                        "exact_snippets": "Known intolerance to steroid therapy",
                        "criterion": "intolerance to steroid therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known intolerance to steroid therapy",
                        "criterion": "intolerance to steroid therapy",
                        "requirement": {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known intolerance to steroid therapy",
                                "criterion": "intolerance to steroid therapy",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Known intolerance to steroid therapy",
                                "criterion": "intolerance to steroid therapy",
                                "requirement": {
                                    "requirement_type": "knowledge_status",
                                    "expected_value": "known"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with hepatic impairment, defined as bilirubin ≥ 1.5 x institutional upper limit of normal (ULN) or aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN, within 21 days of initiation of protocol therapy",
                "criterions": [
                    {
                        "exact_snippets": "bilirubin ≥ 1.5 x institutional upper limit of normal (ULN)",
                        "criterion": "bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                        "criterion": "aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                        "criterion": "alkaline phosphatase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 21 days of initiation of protocol therapy",
                        "criterion": "timing of laboratory assessment",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 21 days of initiation of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bilirubin ≥ 1.5 x institutional upper limit of normal (ULN)",
                                "criterion": "bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1.5,
                                        "unit": "x institutional ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "within 21 days of initiation of protocol therapy",
                                "criterion": "timing of laboratory assessment",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 21 days of initiation of protocol therapy"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                                        "criterion": "aspartate aminotransferase (AST)",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                                        "criterion": "alanine aminotransferase (ALT)",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]), or alkaline phosphatase ≥ 3 x institutional ULN",
                                        "criterion": "alkaline phosphatase",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": "x institutional ULN"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "within 21 days of initiation of protocol therapy",
                                "criterion": "timing of laboratory assessment",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 21 days of initiation of protocol therapy"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol",
                "criterions": [
                    {
                        "exact_snippets": "Poor tolerability ... to any of the study drugs",
                        "criterion": "tolerability to study drugs",
                        "requirement": {
                            "requirement_type": "tolerability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known allergy to any of the study drugs",
                        "criterion": "allergy to study drugs",
                        "requirement": {
                            "requirement_type": "allergy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "known allergy to ... compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol",
                        "criterion": "allergy to compounds similar to dexamethasone, boron or mannitol",
                        "requirement": {
                            "requirement_type": "allergy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Poor tolerability ... to any of the study drugs",
                            "criterion": "tolerability to study drugs",
                            "requirement": {
                                "requirement_type": "tolerability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "exact_snippets": "known allergy to any of the study drugs",
                        "criterion": "allergy to study drugs",
                        "requirement": {
                            "requirement_type": "allergy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "known allergy to ... compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol",
                        "criterion": "allergy to compounds similar to dexamethasone, boron or mannitol",
                        "requirement": {
                            "requirement_type": "allergy",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known hypersensitivity to acyclovir or similar anti-viral drug",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to acyclovir or similar anti-viral drug",
                        "criterion": "hypersensitivity to acyclovir or similar anti-viral drug",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to acyclovir or similar anti-viral drug",
                        "criterion": "hypersensitivity to acyclovir or similar anti-viral drug",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with known central nervous system (CNS) involvement",
                "criterions": [
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement",
                        "criterion": "central nervous system (CNS) involvement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement",
                        "criterion": "central nervous system (CNS) involvement",
                        "requirement": {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement",
                        "criterion": "central nervous system (CNS) involvement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement",
                        "criterion": "central nervous system (CNS) involvement",
                        "requirement": {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)",
                "criterions": [
                    {
                        "exact_snippets": "Seropositive for hepatitis C",
                        "criterion": "hepatitis C serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy",
                        "criterion": "sustained virologic response (SVR) to hepatitis C therapy",
                        "requirement": {
                            "requirement_type": "SVR status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy",
                        "criterion": "sustained virologic response (SVR) to hepatitis C therapy",
                        "requirement": {
                            "requirement_type": "aviremia duration after antiviral therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Seropositive for hepatitis C",
                            "criterion": "hepatitis C serostatus",
                            "requirement": {
                                "requirement_type": "seropositivity",
                                "expected_value": true
                            }
                        },
                        {
                            "not_criteria": {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy",
                                        "criterion": "sustained virologic response (SVR) to hepatitis C therapy",
                                        "requirement": {
                                            "requirement_type": "SVR status",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy",
                                        "criterion": "sustained virologic response (SVR) to hepatitis C therapy",
                                        "requirement": {
                                            "requirement_type": "aviremia duration after antiviral therapy",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 12,
                                                "unit": "weeks"
                                            }
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Steroids more than 160 mg IV equivalents of dexamethasone or bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents",
                "criterions": [
                    {
                        "exact_snippets": "Steroids more than 160 mg IV equivalents of dexamethasone",
                        "criterion": "steroid use (dexamethasone equivalents)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mg IV equivalents"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents",
                        "criterion": "bortezomib dosing",
                        "requirement": {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "doses"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents",
                        "criterion": "bortezomib dosing",
                        "requirement": {
                            "requirement_type": "dose per administration",
                            "expected_value": {
                                "operator": "=",
                                "value": 1.3,
                                "unit": "mg/m²"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Steroids more than 160 mg IV equivalents of dexamethasone",
                        "criterion": "steroid use (dexamethasone equivalents)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mg IV equivalents"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents",
                                "criterion": "bortezomib dosing",
                                "requirement": {
                                    "requirement_type": "number of doses",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 2,
                                        "unit": "doses"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "bortezomib > 2 doses of 1.3 mg/m² each dosing equivalents",
                                "criterion": "bortezomib dosing",
                                "requirement": {
                                    "requirement_type": "dose per administration",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 1.3,
                                        "unit": "mg/m²"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior cerebrovascular event with residual neurologic deficit",
                "criterions": [
                    {
                        "exact_snippets": "Prior cerebrovascular event",
                        "criterion": "cerebrovascular event",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "residual neurologic deficit",
                        "criterion": "neurologic deficit",
                        "requirement": {
                            "requirement_type": "residual",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior cerebrovascular event",
                        "criterion": "cerebrovascular event",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "residual neurologic deficit",
                        "criterion": "neurologic deficit",
                        "requirement": {
                            "requirement_type": "residual",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled angina, arrhythmia or hypertension",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... arrhythmia",
                        "criterion": "arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female participants pregnant or breast-feeding",
                "criterions": [
                    {
                        "exact_snippets": "Female participants ... pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Female participants ... breast-feeding",
                        "criterion": "breast-feeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Female participants ... pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Female participants ... breast-feeding",
                        "criterion": "breast-feeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosed with smoldering multiple myeloma (MM), monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis or primary or secondary plasma cell leukemia",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosed with smoldering multiple myeloma (MM)",
                        "criterion": "smoldering multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... monoclonal gammopathy of undetermined significance",
                        "criterion": "monoclonal gammopathy of undetermined significance",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... Waldenstrom's macroglobulinemia",
                        "criterion": "Waldenstrom's macroglobulinemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome",
                        "criterion": "POEMS syndrome",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... amyloidosis",
                        "criterion": "amyloidosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... primary or secondary plasma cell leukemia",
                        "criterion": "primary plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... primary or secondary plasma cell leukemia",
                        "criterion": "secondary plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Diagnosed with smoldering multiple myeloma (MM)",
                        "criterion": "smoldering multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... monoclonal gammopathy of undetermined significance",
                        "criterion": "monoclonal gammopathy of undetermined significance",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... Waldenstrom's macroglobulinemia",
                        "criterion": "Waldenstrom's macroglobulinemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome",
                        "criterion": "POEMS syndrome",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... amyloidosis",
                        "criterion": "amyloidosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... primary or secondary plasma cell leukemia",
                        "criterion": "primary plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosed with ... primary or secondary plasma cell leukemia",
                        "criterion": "secondary plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial",
                "criterions": [
                    {
                        "exact_snippets": "Participation in other clinical trials ... within 30 days of the start of this trial and throughout the duration of this trial",
                        "criterion": "participation in other clinical trials",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participation in other clinical trials ... within 30 days of the start of this trial and throughout the duration of this trial",
                        "criterion": "participation in other clinical trials",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "including those with other investigational agents not included in this trial",
                        "criterion": "participation in trials with other investigational agents not included in this trial",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participation in other clinical trials ... within 30 days of the start of this trial and throughout the duration of this trial",
                                "criterion": "participation in other clinical trials",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Participation in other clinical trials ... within 30 days of the start of this trial and throughout the duration of this trial",
                                "criterion": "participation in other clinical trials",
                                "requirement": {
                                    "requirement_type": "time frame",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 30,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "including those with other investigational agents not included in this trial",
                        "criterion": "participation in trials with other investigational agents not included in this trial",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent) for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to study treatment.)",
                "criterions": [
                    {
                        "exact_snippets": "receiving concomitant therapy with bisphosphonates",
                        "criterion": "bisphosphonate therapy",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                        "criterion": "corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                        "criterion": "corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone equivalent per day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Doses of corticosteroid should be stable for at least 7 days prior to study treatment",
                        "criterion": "corticosteroid dose stability",
                        "requirement": {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "receiving concomitant therapy with bisphosphonates",
                                "criterion": "bisphosphonate therapy",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                                            "criterion": "corticosteroid therapy",
                                            "requirement": {
                                                "requirement_type": "concomitant use",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                                            "criterion": "corticosteroid therapy",
                                            "requirement": {
                                                "requirement_type": "dose",
                                                "expected_value": {
                                                    "operator": "<=",
                                                    "value": 10,
                                                    "unit": "mg prednisone equivalent per day"
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "Doses of corticosteroid should be stable for at least 7 days prior to study treatment",
                                            "criterion": "corticosteroid dose stability",
                                            "requirement": {
                                                "requirement_type": "stability duration",
                                                "expected_value": {
                                                    "operator": ">=",
                                                    "value": 7,
                                                    "unit": "days"
                                                }
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                                "criterion": "corticosteroid therapy",
                                "requirement": {
                                    "requirement_type": "concomitant use",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "receiving concomitant therapy with ... low dose corticosteroids (e.g., prednisone up to but no more than 10 mg p.o. once daily (q.d.) or its equivalent)",
                                            "criterion": "corticosteroid therapy",
                                            "requirement": {
                                                "requirement_type": "dose",
                                                "expected_value": {
                                                    "operator": "<=",
                                                    "value": 10,
                                                    "unit": "mg prednisone equivalent per day"
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "Doses of corticosteroid should be stable for at least 7 days prior to study treatment",
                                            "criterion": "corticosteroid dose stability",
                                            "requirement": {
                                                "requirement_type": "stability duration",
                                                "expected_value": {
                                                    "operator": ">=",
                                                    "value": 7,
                                                    "unit": "days"
                                                }
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any other uncontrolled or severe cardiovascular condition",
                "criterions": [
                    {
                        "exact_snippets": "Any other uncontrolled or severe cardiovascular condition",
                        "criterion": "cardiovascular condition",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Any other uncontrolled or severe cardiovascular condition",
                        "criterion": "cardiovascular condition",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any other uncontrolled or severe cardiovascular condition",
                        "criterion": "cardiovascular condition",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Any other uncontrolled or severe cardiovascular condition",
                        "criterion": "cardiovascular condition",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study",
                "criterions": [
                    {
                        "exact_snippets": "Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study",
                        "criterion": "any condition (including laboratory abnormalities)",
                        "requirement": {
                            "requirement_type": "risk assessment by investigator",
                            "expected_value": "unacceptable risk if subject were to participate in the study"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study",
                        "criterion": "any condition (including laboratory abnormalities)",
                        "requirement": {
                            "requirement_type": "risk assessment by investigator",
                            "expected_value": "unacceptable risk if subject were to participate in the study"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with an absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation. Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                "criterions": [
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1000,
                                "unit": "cells/mm³"
                            }
                        }
                    },
                    {
                        "exact_snippets": "absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at time of screening evaluation"
                        }
                    },
                    {
                        "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                        "criterion": "growth factor use",
                        "requirement": {
                            "requirement_type": "use to meet ANC eligibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                        "criterion": "growth factor use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                        "criterion": "growth factor use",
                        "requirement": {
                            "requirement_type": "reference event",
                            "expected_value": "obtaining screening evaluation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation",
                                "criterion": "absolute neutrophil count (ANC)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1000,
                                        "unit": "cells/mm³"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "absolute neutrophil count (ANC) ≤ 1000 cells/mm³ at time of screening evaluation",
                                "criterion": "absolute neutrophil count (ANC)",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "at time of screening evaluation"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                                "criterion": "growth factor use",
                                "requirement": {
                                    "requirement_type": "use to meet ANC eligibility",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                                "criterion": "growth factor use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Growth factors may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation",
                                "criterion": "growth factor use",
                                "requirement": {
                                    "requirement_type": "reference event",
                                    "expected_value": "obtaining screening evaluation"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75000,
                                "unit": "cells/mm³"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "time of measurement",
                            "expected_value": "at time of screening evaluation"
                        }
                    },
                    {
                        "exact_snippets": "Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "allowed within 3 days before study enrollment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation",
                                "criterion": "platelet count",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 75000,
                                        "unit": "cells/mm³"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Platelet count ≤ 75,000 cells/mm³ at time of screening evaluation",
                                "criterion": "platelet count",
                                "requirement": {
                                    "requirement_type": "time of measurement",
                                    "expected_value": "at time of screening evaluation"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "allowed within 3 days before study enrollment",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known significant cardiac abnormalities including:",
                "criterions": [
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "Known significant cardiac abnormalities",
                        "criterion": "cardiac abnormalities",
                        "requirement": {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Bone lesions: 1 or more osteolytic lesions on skeletal radiography, computed tomography (CT), or magnetic resonance imaging (MRI)",
                "criterions": [
                    {
                        "exact_snippets": "Bone lesions: 1 or more osteolytic lesions on skeletal radiography, computed tomography (CT), or magnetic resonance imaging (MRI)",
                        "criterion": "osteolytic bone lesions",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Bone lesions: 1 or more osteolytic lesions on skeletal radiography, computed tomography (CT), or magnetic resonance imaging (MRI)",
                        "criterion": "osteolytic bone lesions",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "skeletal radiography",
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)",
                "criterions": [
                    {
                        "exact_snippets": "Agree to practice true abstinence",
                        "criterion": "sexual abstinence",
                        "requirement": {
                            "requirement_type": "agreement to practice",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "when this is in line with the preferred and usual lifestyle of the subject",
                        "criterion": "abstinence as usual lifestyle",
                        "requirement": {
                            "requirement_type": "consistency with usual lifestyle",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "method exclusion",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), or immunoglobulin M (IgM) multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or",
                "criterions": [
                    {
                        "exact_snippets": "Immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), or immunoglobulin M (IgM) multiple myeloma",
                        "criterion": "multiple myeloma immunoglobulin subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "IgA",
                                "IgD",
                                "IgE",
                                "IgM"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "serum M-protein level ≥ 0.5 g/dL",
                        "criterion": "serum M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "urine M-protein level ≥ 200 mg/24 hours",
                        "criterion": "urine M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* These values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The involved FLC must be ≥ 100 mg/L",
                "criterions": [
                    {
                        "exact_snippets": "The involved FLC must be ≥ 100 mg/L",
                        "criterion": "involved free light chain (FLC) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "The involved FLC must be \u001e 100 mg/L",
                        "criterion": "involved free light chain (FLC) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used",
                "criterions": [
                    {
                        "exact_snippets": "Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence",
                        "criterion": "clonality",
                        "requirement": {
                            "requirement_type": "establishment_method",
                            "expected_value": [
                                "kappa/lambda-light-chain restriction on flow cytometry",
                                "immunohistochemistry",
                                "immunofluorescence"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used",
                        "criterion": "bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "estimation_method",
                            "expected_value": "core biopsy specimen"
                        }
                    },
                    {
                        "exact_snippets": "Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used",
                        "criterion": "bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "disparity_resolution",
                            "expected_value": "use highest value between aspirate and core biopsy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)",
                "criterions": [
                    {
                        "exact_snippets": "Agree to practice true abstinence",
                        "criterion": "sexual abstinence",
                        "requirement": {
                            "requirement_type": "agreement to practice",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agree to practice true abstinence",
                        "criterion": "sexual abstinence",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "true abstinence"
                        }
                    },
                    {
                        "exact_snippets": "when this is in line with the preferred and usual lifestyle of the subject",
                        "criterion": "abstinence as usual lifestyle",
                        "requirement": {
                            "requirement_type": "consistency with lifestyle",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "method exclusion",
                            "expected_value": [
                                "periodic abstinence",
                                "calendar method",
                                "ovulation method",
                                "symptothermal method",
                                "post-ovulation method",
                                "withdrawal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Have documented multiple myeloma as defined by the International Myeloma Working Group (IMWG) 2014 criteria including: Clonal bone marrow plasma cells ≥ 10% (If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement). In addition, the patient must meet one of the criteria in d1 or d2:",
                "criterions": [
                    {
                        "exact_snippets": "documented multiple myeloma as defined by the International Myeloma Working Group (IMWG) 2014 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "as defined by IMWG 2014 criteria"
                        }
                    },
                    {
                        "exact_snippets": "Clonal bone marrow plasma cells ≥ 10%",
                        "criterion": "clonal bone marrow plasma cells",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required",
                        "criterion": "bone lesions",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "documented multiple myeloma as defined by the International Myeloma Working Group (IMWG) 2014 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "as defined by IMWG 2014 criteria"
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "Clonal bone marrow plasma cells \u0010 10%",
                            "criterion": "clonal bone marrow plasma cells",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 10,
                                    "unit": "%"
                                }
                            }
                        },
                        "then_criteria": null,
                        "else_criteria": {
                            "exact_snippets": "If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required",
                            "criterion": "bone lesions",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 1,
                                    "unit": "lesion"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used",
                "criterions": [
                    {
                        "exact_snippets": "Clonality should be established by showing kappa/lambda-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence",
                        "criterion": "clonality",
                        "requirement": {
                            "requirement_type": "establishment_method",
                            "expected_value": [
                                "kappa/lambda-light-chain restriction on flow cytometry",
                                "immunohistochemistry",
                                "immunofluorescence"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen",
                        "criterion": "bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "estimation_method",
                            "expected_value": "core biopsy specimen"
                        }
                    },
                    {
                        "exact_snippets": "in case of a disparity between the aspirate and core biopsy, the highest value should be used",
                        "criterion": "bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "disparity_resolution",
                            "expected_value": "use highest value between aspirate and core biopsy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours. Note: All attempts should be made to determine eligibility of the subject based on the central laboratory results of screening blood and urine M-protein measurements. In exceptional circumstances, the local laboratory results for blood and urine M-protein measurements may be used to determine eligibility, but only if the results are clearly (eg, 25% or more) above the thresholds for measurability; or",
                "criterions": [
                    {
                        "exact_snippets": "Serum M-protein level ≥ 1.0 g/dL",
                        "criterion": "serum M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "urine M-protein level ≥ 200 mg/24 hours",
                        "criterion": "urine M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum M-protein level \u001e 1.0 g/dL",
                        "criterion": "serum M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "urine M-protein level \u001e 200 mg/24 hours",
                        "criterion": "urine M-protein level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International Unit (mIU)/mL within 10-14 days prior to and again within 24 hours of starting study drugs",
                "criterions": [
                    {
                        "exact_snippets": "Females of childbearing potential (FCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Females of childbearing potential (FCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative serum or urine pregnancy test",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "must have a negative serum or urine pregnancy test",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "with a sensitivity of at least 50 milli-International Unit (mIU)/mL",
                        "criterion": "pregnancy test sensitivity",
                        "requirement": {
                            "requirement_type": "sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mIU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 10-14 days prior to and again within 24 hours of starting study drugs",
                        "criterion": "timing of pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "within 10-14 days prior to starting study drugs",
                                "within 24 hours of starting study drugs"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Clonal bone marrow plasma cell percentage ≥ 60%",
                "criterions": [
                    {
                        "exact_snippets": "Clonal bone marrow plasma cell percentage ≥ 60%",
                        "criterion": "clonal bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Clonal bone marrow plasma cell percentage  60%",
                        "criterion": "clonal bone marrow plasma cell percentage",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Light chain multiple myeloma without measurable disease in the urine: serum Ig FLC ≥ 10 mg/dL and abnormal serum Ig kappa/lambda FLC ratio",
                "criterions": [
                    {
                        "exact_snippets": "Light chain multiple myeloma",
                        "criterion": "light chain multiple myeloma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without measurable disease in the urine",
                        "criterion": "measurable disease in the urine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "serum Ig FLC ≥ 10 mg/dL",
                        "criterion": "serum Ig FLC",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "abnormal serum Ig kappa/lambda FLC ratio",
                        "criterion": "serum Ig kappa/lambda FLC ratio",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Light chain multiple myeloma",
                        "criterion": "light chain multiple myeloma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without measurable disease in the urine",
                        "criterion": "measurable disease in the urine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "serum Ig FLC \u001e 10 mg/dL",
                        "criterion": "serum Ig FLC",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "abnormal serum Ig kappa/lambda FLC ratio",
                        "criterion": "serum Ig kappa/lambda FLC ratio",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Renal insufficiency, defined as creatinine clearance ≤ 30 mL/min (either actual or calculated value), within 21 days of initiation of protocol therapy. The Cockcroft-Gault formula should be used for calculating creatinine clearance values",
                "criterions": [
                    {
                        "exact_snippets": "Renal insufficiency, defined as creatinine clearance ≤ 30 mL/min (either actual or calculated value), within 21 days of initiation of protocol therapy. The Cockcroft-Gault formula should be used for calculating creatinine clearance values",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Renal insufficiency, defined as creatinine clearance ≤ 30 mL/min (either actual or calculated value), within 21 days of initiation of protocol therapy. The Cockcroft-Gault formula should be used for calculating creatinine clearance values",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "actual value",
                                "calculated value (Cockcroft-Gault formula)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Renal insufficiency, defined as creatinine clearance ≤ 30 mL/min (either actual or calculated value), within 21 days of initiation of protocol therapy. The Cockcroft-Gault formula should be used for calculating creatinine clearance values",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 21 days of initiation of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosed or treated for another malignancy within 2 years before study enrollment",
                        "criterion": "history of another malignancy",
                        "requirement": {
                            "requirement_type": "diagnosis or treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years before study enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "previously diagnosed with another malignancy and have any evidence of residual disease",
                        "criterion": "residual disease from previous malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection",
                        "criterion": "nonmelanoma skin cancer or carcinoma in situ",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "nonmelanoma skin cancer",
                                "carcinoma in situ"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection",
                        "criterion": "nonmelanoma skin cancer or carcinoma in situ",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "complete resection"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participant has ≥ grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                "criterions": [
                    {
                        "exact_snippets": "Participant has ≥ grade 3 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                        "criterion": "peripheral neuropathy with pain",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                        "criterion": "peripheral neuropathy with pain",
                        "requirement": {
                            "requirement_type": "pain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                        "criterion": "peripheral neuropathy with pain",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 21 days before initiation of protocol therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participant has \u0000\u00000\u0000e2\u000089\u0000e2\u000089\u0000a5 grade 3 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                                "criterion": "peripheral neuropathy with pain",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 2,
                                        "unit": "grade"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                                "criterion": "peripheral neuropathy with pain",
                                "requirement": {
                                    "requirement_type": "pain",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "grade 2 with pain on clinical examination within 21 days before initiation of protocol therapy",
                                "criterion": "peripheral neuropathy with pain",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 21 days before initiation of protocol therapy"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery",
                "criterions": [
                    {
                        "exact_snippets": "undergone major surgery ≤ 4 weeks prior to starting study drug",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have not recovered from side effects of the surgery",
                        "criterion": "recovery from side effects of surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "undergone major surgery \u0010 4 weeks prior to starting study drug",
                            "criterion": "major surgery",
                            "requirement": {
                                "requirement_type": "time since surgery",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "have not recovered from side effects of the surgery",
                            "criterion": "recovery from side effects of surgery",
                            "requirement": {
                                "requirement_type": "recovery status",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification",
                "criterions": [
                    {
                        "exact_snippets": "Has known moderate or severe persistent asthma within the past 2 years",
                        "criterion": "persistent asthma",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Has known moderate or severe persistent asthma within the past 2 years",
                        "criterion": "persistent asthma",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has known moderate or severe persistent asthma within the past 2 years",
                        "criterion": "persistent asthma",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "currently has uncontrolled asthma of any classification",
                        "criterion": "asthma",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "currently has uncontrolled asthma of any classification",
                        "criterion": "asthma",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "current"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participants with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff",
                "criterions": [
                    {
                        "exact_snippets": "any significant history of non-compliance to medical regimens",
                        "criterion": "history of non-compliance to medical regimens",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                        "criterion": "ability or willingness to comply with study staff instructions",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                        "criterion": "ability or willingness to comply with study staff instructions",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any significant history of non-compliance to medical regimens",
                        "criterion": "history of non-compliance to medical regimens",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                                "criterion": "ability or willingness to comply with study staff instructions",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                                "criterion": "ability or willingness to comply with study staff instructions",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                                "criterion": "ability or willingness to comply with study staff instructions",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "unwilling or unable to comply with the instructions given to him/her by the study staff",
                                "criterion": "ability or willingness to comply with study staff instructions",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serious, intercurrent illness including, but not limited to, clinically relevant active infection, uncontrolled diabetes mellitus, or serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis",
                "criterions": [
                    {
                        "exact_snippets": "Serious, intercurrent illness",
                        "criterion": "serious intercurrent illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "clinically relevant active infection",
                        "criterion": "clinically relevant active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes mellitus",
                        "criterion": "uncontrolled diabetes mellitus",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis",
                        "criterion": "serious co-morbid medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic restrictive pulmonary disease",
                        "criterion": "chronic restrictive pulmonary disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "cirrhosis",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serious, intercurrent illness",
                        "criterion": "serious intercurrent illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically relevant active infection",
                        "criterion": "clinically relevant active infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes mellitus",
                        "criterion": "uncontrolled diabetes mellitus",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serious co-morbid medical conditions such as chronic restrictive pulmonary disease, and cirrhosis",
                        "criterion": "serious co-morbid medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic restrictive pulmonary disease",
                        "criterion": "chronic restrictive pulmonary disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cirrhosis",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Congestive heart failure, New York Heart Association (NYHA) class III or IV",
                "criterions": [
                    {
                        "exact_snippets": "Congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association (NYHA) class III or IV",
                        "criterion": "NYHA class",
                        "requirement": {
                            "requirement_type": "classification",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol",
                "criterions": [
                    {
                        "exact_snippets": "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol",
                        "criterion": "serious medical or psychiatric illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol",
                        "criterion": "serious medical or psychiatric illness",
                        "requirement": {
                            "requirement_type": "potential to interfere with completion of treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol",
                        "criterion": "serious medical or psychiatric illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol",
                        "criterion": "serious medical or psychiatric illness",
                        "requirement": {
                            "requirement_type": "potential to interfere with completion of treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}